TearLab™ Osmolarity system Wins Medical Design Excellence Award
SAN DIEGO, CA – April 8, 2009 - OccuLogix, Inc. dba TearLab Corporation (NASDAQ: TEAR and TSX: TLB) today announced that its TearLab™ Osmolarity System has received a 2009 Medical Design Excellence Award (MDEA).
The Medical Design Excellence Awards competition is organized and presented by Canon Communications LLC (Los Angeles) and is the only awards program that exclusively recognizes contributions and advances in the design of medical products. Entries are evaluated on the basis of their design and engineering features, including innovative use of materials, user-related functions that improve healthcare delivery and change traditional medical attitudes or practices, features that provide enhanced benefits to the patient, and the ability of the product development team to overcome design and engineering challenges so that the product meets its clinical objectives.
A comprehensive review of the entries was performed by an impartial, multidisciplinary panel of third-party jurors with expertise in biomedical engineering, human factors, industrial design, medicine, and diagnostics.
“We are honored to be recognized by the MDEA judges,” said Eric Donsky, CEO TearLab Corporation. “Receiving the prestigious Medical Design Excellence Award is a validation that our TearLab™ technology represents a breakthrough in the development of innovative, point-of-care diagnostic products. Our engineering team, led by Dr. Benjamin Sullivan and Steve Zmina, along with our dedicated partners, Minifab & Invetech, worked tirelessly to overcome the many challenges of establishing a product capable of precisely measuring a diagnostic marker in 50 nanoliters of tears within seconds while maintaining a simple user interface for a technician to achieve repeatable results in an office setting. We thank the judges for their appreciation of the huge potential of TearLab™ as a non-invasive diagnostic platform.”
The 2009 Medical Design Excellence Award winners will be honored at a ceremony during the Medical Design & Manufacturing (MD&M) East Conference and Exposition, June 9-11, 2009, at New York City’s Jacob Javits Convention Center.
About OccuLogix, Inc. dba TearLab Corporation
OccuLogix dba TearLab Corporation (www.tearlab.com) is an ophthalmic device company developing and commercializing novel, lab-on-a-chip technologies (integrating one or several laboratory functions on a chip only millimeters in size) that enable eye care practitioners to test for highly sensitive and specific biomarkers in tears at the point-of-care.
This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.
For Further Information Please Contact: